ALCOHOL; CHLORHEXIDINE GLUCONATE - Generic Drug Details

What are the generic drug sources for alcohol; chlorhexidine gluconate and what is the scope of freedom to operate?

Alcohol; chlorhexidine gluconate is the generic ingredient in one branded drug marketed by 3M and is included in one NDA. Additional information is available in the individual branded drug profile pages.

One supplier is listed for this compound.

Summary for ALCOHOL; CHLORHEXIDINE GLUCONATE

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Clinical Trials:	38
DailyMed Link:	ALCOHOL; CHLORHEXIDINE GLUCONATE at DailyMed

Recent Clinical Trials for ALCOHOL; CHLORHEXIDINE GLUCONATE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Yaneve Fonge	Phase 4
Sunnybrook Health Sciences Centre	Phase 4
Rafik Batroussy	Phase 2

See all ALCOHOL; CHLORHEXIDINE GLUCONATE clinical trials

Pharmacology for ALCOHOL; CHLORHEXIDINE GLUCONATE

Physiological Effect

Decreased Cell Wall Integrity

Anatomical Therapeutic Chemical (ATC) Classes for ALCOHOL; CHLORHEXIDINE GLUCONATE

A01AB	Antiinfectives and antiseptics for local oral treatment
A01A	STOMATOLOGICAL PREPARATIONS
A01	STOMATOLOGICAL PREPARATIONS
A	Alimentary tract and metabolism

B05CA	Antiinfectives
B05C	IRRIGATING SOLUTIONS
B05	BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS
B	Blood and blood forming organs

D08AC	Biguanides and amidines
D08A	ANTISEPTICS AND DISINFECTANTS
D08	ANTISEPTICS AND DISINFECTANTS
D	Dermatologicals

D09AA	Medicated dressings with antiinfectives
D09A	MEDICATED DRESSINGS
D09	MEDICATED DRESSINGS
D	Dermatologicals

R02AA	Antiseptics
R02A	THROAT PREPARATIONS
R02	THROAT PREPARATIONS
R	Respiratory system

S01AX	Other antiinfectives
S01A	ANTIINFECTIVES
S01	OPHTHALMOLOGICALS
S	Sensory organs

S02AA	Antiinfectives
S02A	ANTIINFECTIVES
S02	OTOLOGICALS
S	Sensory organs

S03AA	Antiinfectives
S03A	ANTIINFECTIVES
S03	OPHTHALMOLOGICAL AND OTOLOGICAL PREPARATIONS
S	Sensory organs

US Patents and Regulatory Information for ALCOHOL; CHLORHEXIDINE GLUCONATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
3m	AVAGARD	alcohol; chlorhexidine gluconate	SOLUTION;TOPICAL	021074-001	Jun 7, 2001		OTC	Yes	Yes

Expired US Patents for ALCOHOL; CHLORHEXIDINE GLUCONATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
3m	AVAGARD	alcohol; chlorhexidine gluconate	SOLUTION;TOPICAL	021074-001	Jun 7, 2001	5,897,031
3m	AVAGARD	alcohol; chlorhexidine gluconate	SOLUTION;TOPICAL	021074-001	Jun 7, 2001	7,566,460
3m	AVAGARD	alcohol; chlorhexidine gluconate	SOLUTION;TOPICAL	021074-001	Jun 7, 2001	6,090,395
3m	AVAGARD	alcohol; chlorhexidine gluconate	SOLUTION;TOPICAL	021074-001	Jun 7, 2001	7,081,246
3m	AVAGARD	alcohol; chlorhexidine gluconate	SOLUTION;TOPICAL	021074-001	Jun 7, 2001	6,623,744
3m	AVAGARD	alcohol; chlorhexidine gluconate	SOLUTION;TOPICAL	021074-001	Jun 7, 2001	6,534,069

ALCOHOL; CHLORHEXIDINE GLUCONATE Market Analysis and Financial Projection

Last updated: February 17, 2026

What Are the Market Dynamics for Chlorhexidine Gluconate?

Chlorhexidine gluconate, an antiseptic used mainly in oral rinses, skin disinfectants, and surgical scrubs, faces steady demand driven by its efficacy against a broad spectrum of pathogens and its established role in infection control. Key market drivers include increasing hospital-acquired infection rates, rising adoption of antiseptic protocols in dental and surgical settings, and growing awareness of antimicrobial resistance.

Market Size and Growth:
As of 2022, the global chlorhexidine market was valued at approximately $1.4 billion. The compound's market is expected to grow at a compound annual growth rate (CAGR) of 4-5% through 2027. The surge is attributed to expanding healthcare infrastructure, especially in Asia-Pacific, and increased use in consumer health products.

Regional Insights:
North America holds the largest market share, driven by high healthcare expenditure and stringent infection control standards. Europe follows, with growth supported by aging populations and hospital infection control policies. Asia-Pacific exhibits the fastest growth, fueled by developing healthcare systems, rising urbanization, and increased dental care awareness.

Market Challenges:
Key issues include the emergence of chlorhexidine resistance, regulatory restrictions in some regions (e.g., EU's use limits in oral products), and concerns about side effects such as skin irritation and rare allergic reactions. Additionally, competition from alternative antiseptics, such as povidone-iodine or alcohol-based solutions, constrains growth prospects.

Market Opportunities:
Innovations in formulations, such as sustained-release topical products, and expansion into non-traditional sectors like textiles and livestock disinfection present potential growth avenues. The COVID-19 pandemic heightened demand for antiseptics, though regulatory scrutiny and supply chain disruptions affected the market.

What Is the Financial Trajectory for Chlorhexidine Gluconate Products?

Leading Companies and Revenue:
Major players include Johnson & Johnson, Meda Pharmaceuticals, and Sun Pharmaceutical Industries. Johnson & Johnson’s mouthwash segment, containing chlorhexidine, generated revenue exceeding $500 million in 2022, representing roughly 35% of the global market share.

Revenue Trends:
Despite steady demand, revenues have plateaued or marginally declined in mature markets due to generic competition and pricing pressures. Conversely, emerging markets show double-digit growth in sales volume, slightly compensating for margin pressures.

Pricing Dynamics:
Generic products drive prices down, with average retail prices decreasing by approximately 3-4% annually. Formulation innovations and brand differentiation sustain premium pricing for patented variants.

Investment and R&D:
Limited R&D investment focuses on reducing resistance, improving delivery systems, and expanding applications. No major new chemical entities have entered the market since the 1980s, with focus rather on formulation improvements and new delivery methods.

Profit Margins and Outlook:
Gross margins typically range from 50-60%. Future profit outlook hinges on patent expirations, regulatory changes, and growth in emerging markets. Companies are consolidating through mergers and acquisitions to sustain market share.

What Policies and Regulatory Factors Influence the Market?

Regulations:
The EU’s Scientific Committee on Consumer Safety (SCCS) has expressed concerns regarding chlorhexidine’s long-term safety, leading to restrictions in oral products. The U.S. FDA classifies chlorhexidine as generally recognized as safe (GRAS) for certain uses, but clearance varies across product categories.

Approval and Labeling:
Manufacturers must comply with regulations concerning labeling, permissible concentrations, and safety warnings. Changes in regulation may hinder or promote specific formulations.

Market Access Barriers:
Patent expirations and regulatory stringency in major markets generate temporary barriers but also open opportunities for generics.

What Are the Key Takeaways?

• The market for chlorhexidine gluconate remains stable, with growth driven by healthcare infection control practices and regional market expansion.
• Revenue centers around mature markets like North America and Europe, with emerging markets offering growth potential.
• Competition from generics and alternative antiseptics pressures pricing and margins.
• Regulatory scrutiny, particularly concerning safety profiles, influences formulation and marketing strategies.
• Innovation in formulations and expanded applications could offset limited pipeline activity and patent expirations.

FAQs

1. What are the main applications of chlorhexidine gluconate?
Oral rinses, surgical skin disinfectants, preoperative antiseptics, wound cleaners, and increasingly in consumer health products.

2. How does resistance affect the market?
Reports of bacterial resistance diminish chlorhexidine’s perceived efficacy, prompting increased research and regulatory review.

3. What recent regulatory changes impact the market?
The EU restricts chlorhexidine in certain oral applications; the U.S. maintains broad approvals but with safety warnings.

4. Are there significant patent protections remaining?
Most formulations are off patent; novel delivery systems and formulations are proprietary, providing some competitive advantage.

5. What future trends can influence the market?
Emergent resistance concerns, regulatory adaptations, and product innovations, particularly sustained-release formulations and new application areas.

---

Sources:

1. MarketsandMarkets. Chlorhexidine Gluconate Market - Global Forecast 2022-2027.
2. Johnson & Johnson. 2022 Annual Report.
3. European Chemicals Agency. Assessment of Chlorhexidine Use.
4. U.S. Food and Drug Administration. FDA Regulatory Overview.
5. Grand View Research. Antiseptic Market Analysis.